ARCHIVED: John Mendelsohn, MD Anderson President Emeritus, Passes Away
John Mendelsohn, M.D., president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer therapy, died Jan. 7 at his home in Houston. He was 82. The cause of death was glioblastoma, an aggressive form of brain cancer with which he was diagnosed 15 months ago.
Mendelsohn was the third president...
ARCHIVED: MD Anderson to build new outpatient center in West Houston
MD Anderson News Release 08/20/2015
With the approval of The University of Texas System Board of Regents today, The University of Texas...
ARCHIVED: Same cancer, different time zone
Discovery of Role of Molecular Clocks in Tumor Growth May Impact Breast Cancer Treatment
MD Anderson News Release 07/30/14
ARCHIVED: Skp2 activates cancer-promoting, glucose-processing Akt
E3 ligase’s role makes it target for defeating Herceptin resistance, stifling cancer’s preferred diet
MD Anderson News Release 05/25/2012
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.
This chain of events, the scientists found, promotes...
ARCHIVED: AML Patients Have High Response Rate with Vorinostat Added to Treatment
National Phase III clinical trial will test histone deacetylase inhibitor with frontline therapy
MD Anderson News Release...
ARCHIVED: Protein Wields Phosphate Group to Inhibit Cancer Metastasis
Tagging an enzyme with chemical also is crucial to bone cell formation
MD Anderson News Release 01/03/11
By sticking a chemical...